The effectiveness of immune checkpoint blockade therapy has recently been investigated in an open-label phase II study of anti-PD-1 monotherapy in patients with histological evidence of metastatic or surgically unresectable locally advanced sarcoma. This evidence concerns the gene PDCD1 and sarcoma.